Saladax, Transmedic Partner to Distribute Oncology Dosing Assays in Singapore, Hong Kong | GenomeWeb

NEW YORK (GenomeWeb News) – Saladax on Friday said that it has reached a distribution deal with Transmedic covering Saladax's MyCare oncology therapeutic dose management assays in Singapore and Hong Kong.

The MyCare assays include My5-FU, MyPaclitaxel, and MyDocetaxel products, which guide physicians in maintaining an optimal therapeutic range during the period of treatment, the Bethlehem, Penn.-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.